RT Journal Article
T1 Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection.
A1 Ferra-Murcia, Sergio
A1 Collado-Romacho, Antonio Ramón
A1 Nievas-Soriano, Bruno José
A1 Reche-Lorite, Fernando
A1 Parrón-Carreño, Tesifón
K1 HCV/HIV co-infected
K1 before-after DAA therapy
K1 comorbidity PLWHIV
K1 direct-acting antivirals
K1 metabolic impact
AB Treatment with interferon-free direct-acting antivirals (DAA) has become the gold standard in chronic hepatitis C virus (HCV) infection. Nevertheless, little research about the metabolic impact of achieving sustained virological response (SVR) is available in HCV/HIV co-infected patients. This research aimed to evaluate early anthropometric, lipid and liver parameters changes after achieving SVR 12 weeks after treatment (SVR12). A real-life retrospective descriptive before-after study assessed 128 DAA treatment episodes from 2015 to 2019 in HCV/HIV co-infected patients. Anthropometric parameters (weight, body mass index), lipid profile, genotype (GT) and viral load, liver data (basics laboratory necroinflammatory parameters and transient elastography (TE)) were collected before treatment with DAA (baseline), and when SVR12 was achieved. Significant increases (p
SN 2077-0383
YR 2022
FD 2022-05-07
LK http://hdl.handle.net/10668/21283
UL http://hdl.handle.net/10668/21283
LA en
DS RISalud
RD Apr 6, 2025